Manchester Centre for Genomic Medicine, St. Mary's Hospital, Central Manchester NHS Trust, Manchester Academic Health Science Centre, Manchester, UK.
Divison of Evolution and Genomic Sciences, School of Biology, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Arch Dis Child. 2017 Nov;102(11):1019-1029. doi: 10.1136/archdischild-2017-312738. Epub 2017 May 3.
Inborn errors of metabolism (IEMs) underlie a substantial proportion of paediatric disease burden but their genetic diagnosis can be challenging using the traditional approaches.
We designed and validated a next-generation sequencing (NGS) panel of 226 IEM genes, created six overlapping phenotype-based subpanels and tested 102 individuals, who presented clinically with suspected childhood-onset IEMs.
In 51/102 individuals, NGS fully or partially established the molecular cause or identified other actionable diagnoses. Causal mutations were identified significantly more frequently when the biochemical phenotype suggested a specific IEM or a group of IEMs (p<0.0001), demonstrating the pivotal role of prior biochemical testing in guiding NGS analysis. The NGS panel helped to avoid further invasive, hazardous, lengthy or expensive investigations in 69% individuals (p<0.0001). Additional functional testing due to novel or unexpected findings had to be undertaken in only 3% of subjects, demonstrating that the use of NGS does not significantly increase the burden of subsequent follow-up testing. Even where a molecular diagnosis could not be achieved, NGS-based approach assisted in the management and counselling by reducing the likelihood of a high-penetrant genetic cause.
NGS has significant clinical utility for the diagnosis of IEMs. Biochemical testing and NGS analysis play complementary roles in the diagnosis of IEMs. Incorporating NGS into the diagnostic algorithm of IEMs can improve the accuracy of diagnosis.
先天性代谢缺陷(IEMs)是儿童疾病负担的重要组成部分,但使用传统方法进行遗传诊断具有挑战性。
我们设计并验证了一个包含 226 个 IEM 基因的下一代测序(NGS)面板,创建了六个基于重叠表型的子面板,并对 102 名具有疑似儿童期起病 IEM 临床表现的个体进行了测试。
在 102 名个体中,NGS 完全或部分确定了分子病因或确定了其他可采取行动的诊断。当生化表型提示特定的 IEM 或一组 IEM 时,更频繁地鉴定出因果突变(p<0.0001),这表明在指导 NGS 分析时,先前的生化检测具有关键作用。NGS 面板有助于避免 69%的个体进行进一步的侵入性、危险、冗长或昂贵的调查(p<0.0001)。由于新的或意外的发现而需要进行额外的功能测试的个体仅占 3%,这表明使用 NGS 并不会显著增加后续随访测试的负担。即使无法实现分子诊断,基于 NGS 的方法也通过降低高外显率遗传原因的可能性来辅助管理和咨询。
NGS 在 IEMs 的诊断中具有重要的临床应用价值。生化检测和 NGS 分析在 IEMs 的诊断中发挥互补作用。将 NGS 纳入 IEMs 的诊断算法可以提高诊断的准确性。